Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective

Schwander B, Klesper K, Rossol S, Herrmann K, Zoellner YF

ClinicoEconomics and Outcomes Research 2024, 16:483-492

Published Date: 6 June 2024